Synchron Raises $200 Million to Advance Brain-Computer Interface
Synchron, a New York-based brain-computer interface (BCI) company, secured $200 million in Series D funding, increasing its total funding to $345 million.
Funding Round Details
- Led by Double Point Ventures
- Existing investors: ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, METIS
- New investors: Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, IQT
Technology Overview
Synchron's Stentrode BCI is a non-surgical, endovascular platform designed to enhance mobility, communication, and independence in people with paralysis. It is implanted in the brain via a catheter through blood vessels, interfacing with the motor cortex to record and transmit neural signals.
“The BCI translates brain activity into digital commands, allowing users to control digital devices hands-free.”
Clinical Trials and Commercial Plans
The device is currently in clinical trials with 10 paralysis patients in Australia and the U.S. Funds raised will be used to accelerate these trials and the commercialization process.
Expansion of Operations
- New York: Expansion of in-house operations and cognitive AI division focused on training models from brain data
- San Diego: Growth of the engineering hub
Author's Summary
Synchron advances its brain-computer interface technology with $200 million funding aimed at clinical trials, commercialization, and expanding innovative AI and engineering teams.